{
    "symbol": "LLY",
    "slug": "lly",
    "display_name": "LLY",
    "category": "stocks",
    "region": "US",
    "description": null,
    "url": "https://finscans.com/asset/lly",
    "lang": "en",
    "as_of": "2026-05-22T14:38:58+00:00",
    "stats_30d": {
        "total_signals": 2,
        "bullish": 1,
        "bearish": 1,
        "neutral": 0,
        "explicit": 1,
        "inferred": 1,
        "avg_impact": 5.5,
        "avg_confidence": 70,
        "last_signal_at": "2026-05-22 13:51:05",
        "article_count": 2
    },
    "top_catalysts": [
        {
            "text": "Supreme Court denies appeal on $194 million Medicaid penalty",
            "count": 1
        },
        {
            "text": "Immediate earnings charge in upcoming quarter",
            "count": 1
        },
        {
            "text": "Validation of oral GLP-1 category by EMA",
            "count": 1
        },
        {
            "text": "Investor anticipation of Lilly's orforglipron data",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Lilly's strong cash position may mitigate market reaction",
            "count": 1
        },
        {
            "text": "Ruling was expected and priced in",
            "count": 1
        },
        {
            "text": "Novo's oral Wegovy may establish strong brand loyalty before Lilly's launch",
            "count": 1
        },
        {
            "text": "Lilly's orforglipron still in trials with uncertain outcomes",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-05-22 13:51:05",
            "sentiment": "Bullish",
            "impact_score": 5,
            "confidence_score": 60,
            "mention_type": "inferred",
            "timeframe": "mid-term",
            "region": "US",
            "reasoning": "Novo Nordisk’s Wegovy pill recommendation indirectly validates the oral GLP-1 category, potentially benefiting Eli Lilly’s orforglipron candidate. The positive regulatory signal suggests a receptive EMA pathway for similar drugs, bolstering investor confidence in Lilly’s late-stage pipeline. However, Novo’s first-mover advantage in oral could intensify competitive pressure.",
            "article": {
                "title": "Novo Nordisk’s Wegovy Pill Gets EU Panel Backing for Approval",
                "url": "https://finscans.com/news/novo-nordisks-wegovy-pill-gets-eu-panel-backing-for-approval"
            }
        },
        {
            "signal_at": "2026-05-18 15:49:07",
            "sentiment": "Bearish",
            "impact_score": 6,
            "confidence_score": 80,
            "mention_type": "explicit",
            "timeframe": "short-term",
            "region": "US",
            "reasoning": "Eli Lilly (LLY) must pay $194 million after the Supreme Court declined to hear its appeal, finalizing a Medicaid overpayment ruling. The one-time charge will impact near-term earnings, and the legal defeat may raise concerns about the company's litigation exposure.",
            "article": {
                "title": "Eli Lilly Loses Supreme Court Bid, Faces $194 Million Medicaid Payment",
                "url": "https://finscans.com/news/eli-lilly-loses-supreme-court-bid-faces-194-million"
            }
        }
    ]
}